<!DOCTYPE html>



<html lang="en" data-page-id="Home" data-page-category="Homepage" class="no-js" data-isi="overlay">

<!-- Mirrored from www.entyviohcp.com/ by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 14 Feb 2022 03:29:41 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <title>Entyvio® (vedolizumab) | Official HCP Website</title>

    <!-- meta config -->
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

    <!-- meta -->
    <meta name="title" content="Entyvio® (vedolizumab) | Official HCP Website">
    <meta name="description" content="Learn more about Entyvio® (vedolizumab) for moderate to severe ulcerative colitis and Crohn's disease in adults, including clinical studies, MOA, safety profile, dosing, and resources. See Important Safety Information and Prescribing Information.">

    <!-- og meta -->
    <meta property="og:site_name" content="ENTYVIO (vedolizumab)" />
    <meta property="og:title" content="Entyvio® (vedolizumab) Official HCP Site " />
    <meta property="og:description" content="The official Entyvio® site for healthcare professionals. See Detailed Important Safety Information and full Prescribing Information." />
    <meta property="og:image" content="Content/images/logos/Entyvio-logo_OG_image.png" />
    <meta property="og:url" content="index.html" />
    <meta property="og:type" content="Article" />
    <meta property="fb:app_id" content="312730800454655" />
    <meta name="facebook-domain-verification" content="wz6o5lhbmua917okvlh37j5coqh7vv" />

    <!-- favicon -->
    <link rel="icon" href="Content/images/logos/favicon.png" type="image/x-icon" />
    <link rel="shortcut icon" href="Content/images/logos/favicon.png" type="image/x-icon" />

    <link rel="canonical" href="index.html" />
	<link rel="stylesheet" href="css/core/functions.css" />
	<link rel="stylesheet" href="css/core/global.css" />
	<link rel="stylesheet" href="css/core/functions.css" />
	<link rel="stylesheet" href="css/core/grid.css" />
	<link rel="stylesheet" href="css/core/hero.css" />
	<link rel="stylesheet" href="css/core/print.css" />
	<link rel="stylesheet" href="css/core/reset.css" />
	<link rel="stylesheet" href="css/core/typeface.css" />
	
	<link rel="stylesheet" href="css/components/accordion.css" />
	<link rel="stylesheet" href="css/components/back_to_top.css" />
	<link rel="stylesheet" href="css/components/carousel.css" />
	<link rel="stylesheet" href="css/components/expand.css" />
	<link rel="stylesheet" href="css/components/google_tipbox.css" />
	<link rel="stylesheet" href="css/components/interior_bottom_cta.css" />
	<link rel="stylesheet" href="css/components/modal.css" />
	<link rel="stylesheet" href="css/components/move_ahead.css" />
	<link rel="stylesheet" href="css/components/tab.css" />
	<link rel="stylesheet" href="css/components/video_player.css" />
	
	<link rel="stylesheet" href="css/elements/button.css" />
	<link rel="stylesheet" href="css/elements/form.css" />
	<link rel="stylesheet" href="css/elements/icon.css" />
	<link rel="stylesheet" href="css/elements/table.css" />
	
	<link rel="stylesheet" href="css/layout/body.css" />
	<link rel="stylesheet" href="css/layout/footer.css" />
	<link rel="stylesheet" href="css/layout/header.css" />
	<link rel="stylesheet" href="css/layout/hero.css" />
	<link rel="stylesheet" href="css/layout/indication_bar.css" />
	<link rel="stylesheet" href="css/layout/isi.css" />
	<link rel="stylesheet" href="css/layout/navigation.css" />
	<link rel="stylesheet" href="css/layout/references.css" />

	<link rel="stylesheet" href="css/pages/access_support.css" />
	<link rel="stylesheet" href="css/pages/clinical_efficacy.css" />
	<link rel="stylesheet" href="css/pages/covid.css" />
	<link rel="stylesheet" href="css/pages/dosing_administration.css" />
	<link rel="stylesheet" href="css/pages/error.css" />
	<link rel="stylesheet" href="css/pages/home.css" />
	<link rel="stylesheet" href="css/pages/mechanism_of_action.css" />
	<link rel="stylesheet" href="css/pages/resources.css" />
	<link rel="stylesheet" href="css/pages/safety_profile.css" />
	<link rel="stylesheet" href="css/pages/sitemap.css" />
	
	<script src="https://ajax.googleapis.com/ajax/libs/jquery/3.5.1/jquery.min.js"></script>
    <script rel="preload" src="Scripts/dist/mainbcc9.js?9ACEE82F0D44121C2ABB98FA5832C1193F35EAF57BED54F95179B31DECA5DB1C"></script>
    <script src="Scripts/src/components/digitalData-Entyvio.js"></script>

        <script src="assets.adobedtm.com/8fee56b0a165/6889643c630d/launch-bb8830cef805.min.js"></script>
    <!-- Google Tag Manager -->
<script>
    (function (w, d, s, l, i) {
        w[l] = w[l] || []; w[l].push({
            'gtm.start':
                new Date().getTime(), event: 'gtm.js'
        }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
                'www.googletagmanager.com/gtm5445.html?id=' + i + dl; f.parentNode.insertBefore(j, f);
    })(window, document, 'script', 'dataLayer', 'GTM-M55CCKS');</script>
<!-- End Google Tag Manager -->

    
    <script type="application/ld+json">
		{"@context": "https://schema.org",
		  "@type": "MedicalWebPage",
		  "specialty": "https://schema.org/Gastroenterologic",
		  "audience": "https://schema.org/Clinician",
		  "url": "https://www.entyviohcp.com",
		  "headline": "Entyvio® (vedolizumab) | Official HCP Website",
		  "description": "Learn more about Entyvio® (vedolizumab) for moderate to severe ulcerative colitis and Crohn's disease in adults, including clinical studies, MOA, safety profile, dosing, and resources. See Important Safety Information and Prescribing Information.",

		 "breadcrumb":[
			{"@type":"BreadcrumbList",
			  "itemListElement": [{
			  "@type": "ListItem",
			  "position": "1",
			  "name": "Home",
			  "item": "https://www.entyviohcp.com"}]}],

		 "potentialAction": [
		   {"@type":"ViewAction",
					"name": "Discover the MOA",
					"url":"https://www.entyviohcp.com/mechanism-of-action"},
				{"@type":"ViewAction",
					"name": "View UC data",
					"url":"https://www.entyviohcp.com/clinical-efficacy/ulcerative-colitis/gemini-trial"},
				{"@type":"ViewAction",
					"name": "View the CD data",
					"url":"https://www.entyviohcp.com/clinical-efficacy/crohns-disease/entyvio-placebo-trial"},
                {"@type":"ViewAction",
					"name": "View safety profile",
					"url":"https://www.entyviohcp.com/safety-profile"},
                {"@type":"ViewAction",
					"name": "See the study results",
					"url":"https://www.entyviohcp.com/clinical-efficacy/ulcerative-colitis/varsity-trial"},
                {"@type":"ViewAction",
					"name": "Check coverage",
					"url":"https://www.entyviohcp.com/local-coverage"}],

		 "image": [
			{"@type": "ImageObject",
				"name":"Over 215,000 UC and CD patients in the US since the approval of Entyvio®.",
				"contentUrl": "https://www.entyviohcp.comContent/images/graphics/new-milestones-banner.png"},
			{"@type": "ImageObject",
				"name":"OVER 29K PHYSICIANS HAVE PRESCRIBED ENTYVIO in the US since approval",
				"contentUrl": "https://www.entyviohcp.comContent/images/graphics/29k_icon.png"},
			{"@type": "ImageObject",
				"name":"89% of commercially insured patients have first-line biologic unrestricted commercial coverage.",
				"contentUrl": "https://www.entyviohcp.comContent/images/graphics/89_icon.png"}],

		  "about":
				[{"@type":"Drug",
					"name":"ENTYVIO",
					"nonProprietaryName":"vedolizumab",
					"description":"Indications: Adult Ulcerative Colitis (UC) - ENTYVIO (vedolizumab) is indicated in adults for the treatment of moderately to severely active UC. Adult Crohn's Disease (CD) - ENTYVIO (vedolizumab) is indicated in adults for the treatment of moderately to severely active CD. Please see full Prescribing Information, including Medication Guide.",
                    "warning": ["Important Safety Information.", "ENTYVIO (vedolizumab) for injection is contraindicated in patients who have had a known serious or severe hypersensitivity reaction to ENTYVIO or any of its excipients.", "Infusion-related reactions and hypersensitivity reactions including anaphylaxis, dyspnea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart rate have been reported. These reactions may occur with the first or subsequent infusions and may vary in their time of onset from during infusion or up to several hours post-infusion. If anaphylaxis or other serious infusion-related or hypersensitivity reactions occur, discontinue administration of ENTYVIO immediately and initiate appropriate treatment.", "Patients treated with ENTYVIO are at increased risk for developing infections. Serious infections have been reported in patients treated with ENTYVIO, including anal abscess, sepsis (some fatal), tuberculosis, salmonella sepsis, Listeria meningitis, giardiasis, and cytomegaloviral colitis. ENTYVIO is not recommended in patients with active, severe infections until the infections are controlled. Consider withholding ENTYVIO in patients who develop a severe infection while on treatment with ENTYVIO. Exercise caution in patients with a history of recurring severe infections. Consider screening for tuberculosis (TB) according to the local practice.", "Progressive multifocal leukoencephalopathy (PML), a rare and often fatal opportunistic infection of the central nervous system (CNS), has been reported with systemic immunosuppressants, including another integrin receptor antagonist. PML is caused by the John Cunningham (JC) virus and typically only occurs in patients who are immunocompromised. One case of PML in an ENTYVIO-treated patient with multiple contributory factors has been reported in the post marketing setting (e.g., human immunodeficiency virus [HIV] infection with a CD4 count of 300 cells/mm3 and prior and concomitant immunosuppression). Although unlikely, a risk of PML cannot be ruled out. Monitor patients for any new or worsening neurological signs or symptoms. Typical signs and symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. If PML is suspected, withhold dosing with ENTYVIO and refer to a neurologist; if confirmed, discontinue ENTYVIO dosing permanently.", "There have been reports of elevations of transaminase and/or bilirubin in patients receiving ENTYVIO. ENTYVIO should be discontinued in patients with jaundice or other evidence of significant liver injury.", "Prior to initiating treatment with ENTYVIO, all patients should be brought up to date with all immunizations according to current immunization guidelines. Patients receiving ENTYVIO may receive non-live vaccines and may receive live vaccines if the benefits outweigh the risks.", "Most common adverse reactions (incidence ≥3% and ≥1% higher than placebo): nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, and pain in extremities."],
				    "prescribingInfo": "https://general.takedapharm.com/ENTYVIOPI",
				    "dosageForm": "infusion",
				    "administrationRoute": ["intravenous infusion","IV infusion"],
                    "doseSchedule":
					{"@type": "DoseSchedule",
						"frequency": ": 300 mg infused intravenously over approximately 30 minutes at zero, two and six weeks, then every eight weeks thereafter. "},

			"manufacturer":
					[{"@type": "Corporation",
						"name": "Takeda",
						"logo": "https://www.entyviohcp.comContent/images/logos/logo-takeda.svg"}]}]}
    </script>

</head>


<body>

    <div id="layout">
        <a class="skip-navigation" href="#skip-to-content" target="_self">Skip Navigation</a>
        <header data-device="desktop"> <!-- desktop header, mobile navigation -->
	<div>
        <div class="pushdown">
            <div class="container">
                <div class="flex-container">
    <p class="description">See how we are providing support for your patients during CORONAVIRUS (COVID&#8209;19)</p>
    <a href="covid19.html" class="btn btn-primary">LEARN MORE</a>
</div>
            </div>
        </div>
		<div class="eyebrow">
			<div class="container">
				<nav data-row>
					<ul data-col="mobile-12 desktop-6">
	<li><a href="#isi" target="_self">Important Safety Information</a></li>
	<li><a href="https://general.takedapharm.com/ENTYVIOPI" target="_blank" rel="noreferrer">Prescribing Information</a></li>
	<li><a href="https://general.takedapharm.com/ENTYVIOMG" target="_blank" rel="noreferrer">Medication Guide</a></li>
</ul>

<ul data-col="mobile-12 desktop-6">
	<li><a href="https://www.entyvio.com/" data-modal="external" data-animation="slide" target="_blank" rel="noreferrer">Patient Site</a></li>
	<li class="hcp-site">For U.S. Healthcare Professionals</li>
</ul>
				</nav>
			</div>
		</div>
		<div class="main-nav">
			<div class="container">
				<div class="hcp-text"><p>For U.S. Healthcare Professionals</p></div>
				<div class="logo-container">
					<a class="logo" href="index.html" target="_self"><img src="Content/images/logos/logo-entyvio.svg" alt="Entyvio&reg; (vedolizumab) logo." /></a>
					<button data-mobile-menu aria-expanded="false" aria-label="Close Navigation Menu"><span></span></button>
				</div>
				<nav>
					<!-- NAVIGATION STARTS -->
<ul>
    <li class="active"><a href="index.html" title="Home" target="_self">Home</a></li>

    <li class=" has-submenu clinicalefficacy">
        <a href="clinical-efficacy/ulcerative-colitis/gemini-trial.html" aria-haspopup="true" aria-expanded="false" target="_self"><span>Clinical <br data-only="desktop" />Efficacy</span></a>
        <button id="mobile_nav_trigger_clinicalefficacy" aria-expanded="false"><span class="visuallyhidden">show submenu for Clinical Efficacy</span></button>
        <div class="subnav clinicalefficacy">
            <div class="uc">
                <h3>UC</h3>
                <ul>
                    <li class=""><a href="clinical-efficacy/ulcerative-colitis/gemini-trial.html" target="_self"> GEMINI I: ENTYVIO <em class="vs">vs.</em> PLACEBO</a></li>
                    <li class=""><a href="clinical-efficacy/ulcerative-colitis/varsity-trial.html" target="_self">VARSITY: HEAD-TO-HEAD STUDY</a></li>
                </ul>
            </div>

            <div class="cd">
                <h3>CD</h3>
                <ul>
                    <li class=""><a href="clinical-efficacy/crohns-disease/entyvio-placebo-trial.html" target="_self">GEMINI II AND III: ENTYVIO <em class="vs">vs.</em> PLACEBO</a></li>
                </ul>
            </div>
        </div>
    </li>

    <li class=""><a href="mechanism-of-action.html" target="_self"><span>Mechanism <br data-only="desktop" />of Action</span></a></li>
    <li class=""><a href="safety-profile.html" target="_self"><span>Safety <br data-only="desktop" />Profile</span></a></li>
    <li class=""><a href="dosing-administration.html" target="_self"><span>Dosing &amp; <br data-only="desktop" />Administration</span></a></li>
    <li class=""><a href="access-support/insurance-support.html" target="_self"><span><em data-ec>EntyvioConnect</em></span></a></li>


    
    <li class=" has-submenu resources">
        <a href="resources/professional-resources.html" aria-haspopup="true" aria-expanded="false" target="_self"><span>Resources</span></a>
        <button id="mobile_nav_trigger_resources" aria-expanded="false"><span class="visuallyhidden">show submenu for Resources</span></button>
        <div class="subnav resources">
            <div class="">
                <h3 class=""><a href="resources/professional-resources.html" target="_self">FOR YOU</a></h3>
                <ul>
                    <li class=""><a href="resources/virtual-congress.html" target="_self">ANNUAL CONGRESSES</a></li>
                    <li><a href="https://www.entyviovirtualbooth.com/" data-modal="external" target="_blank">VIRTUAL CONGRESS BOOTH</a></li>
                    <li class=""><a href="resources/peer-perspective.html" target="_self">PEER PERSPECTIVES</a></li>
                    <li class=""><a href="resources/request-a-representative.html" target="_self">REQUEST A REPRESENTATIVE</a></li>
                    <li class=""><a href="resources/clinical-reprints.html" target="_self">CLINICAL REPRINTS</a></li>
                </ul>
            </div>

            <div class="">
                <h3 class=""><a href="resources/patient-resources.html" target="_self">FOR YOUR PATIENTS</a></h3>
                <ul>
                    <li class=""><a href="https://locator.infusioncenter.org/" data-modal="external_third_party" target="_blank">INFUSION CENTER LOCATOR</a></li>
                    <li><a href="https://www.entyvio.com/" data-modal="external" target="_blank" rel="noreferrer">ENTYVIO PATIENT SITE</a></li>
                    <li><a href="local-coverage/index.html" target="_self">ENTYVIO COVERAGE FINDER</a></li>
                </ul>
            </div>
        </div>
    </li>
  
</ul>
        <!-- NAVIGATION ENDS -->

				</nav>
			</div>
		</div>
	</div>
</header>

        <div id="content">
            <header data-device="mobile" data-only="mobile"> <!-- Mobile only header; on desktop, this will hide -->
    <div class="pushdown">
        <div class="container">
            <div class="flex-container">
    <p class="description">See how we are providing support for your patients during CORONAVIRUS (COVID&#8209;19)</p>
    <a href="covid19.html" class="btn btn-primary">LEARN MORE</a>
</div>
        </div>
    </div>
	<div class="for-us-hcp">
		<p>For U.S. Healthcare Professionals</p>
	</div>
	<div>
		<a class="logo" href="index.html" target="_self"><img src="Content/images/logos/logo-entyvio.svg" alt="Entyvio&reg; (vedolizumab) logo." /></a>
		<button data-mobile-menu aria-expanded="false" aria-label="Close Navigation Menu"><span></span></button>
	</div>
	<div class="eyebrow">
		<ul>
			<li><a href="#isi" target="_self">Important Safety Information</a></li>
			<li><a href="https://general.takedapharm.com/ENTYVIOPI" target="_blank" rel="noreferrer">Prescribing Information</a></li>
			<li><a href="https://general.takedapharm.com/ENTYVIOMG" target="_blank" rel="noreferrer">Medication Guide</a></li>
			<li><a href="https://www.entyvio.com/" data-modal="external" data-animation="slide" target="_blank" rel="noreferrer">Patient Site</a></li>
		</ul>
	</div>
</header>

            <main id="body">
                <div id="skip-to-content"></div>
                <!-- ************************* -->
                <!-- **** CODE STARTS **** *** -->
                <!-- ************************* -->

                




<div id="hero">
    <div>
            <picture>
                <source media="screen and (max-width: 959px)" srcset="Content/images/hero/mobile-home-ivette.png">
                <source media="screen and (max-width: 9999px) and (min-width: 960px)" srcset="Content/images/hero/desktop-home-ivette.png">
                <img src="Content/images/hero/desktop-home-ivette.png" alt="Patient." />
            </picture>
            <article>
                <div>
                    <h1>
                        Made for <strong>Selectivity</strong><br />
                        Made for <strong>Remission</strong><br />
                        Made for <strong class="super">Now</strong>
                    </h1>                  

                </div>

                <div class="extra-list">
                    <ul data-bullet="primary">
                        <li>Entyvio works through a gut-selective MOA by specifically binding to the &alpha;4&beta;7 integrin and blocking its interaction with MAdCAM-1, which is mainly expressed on gut endothelial cells.<sup>1-7</sup></li>
                        <li>Remission was evaluated at Week 52.<sup>1</sup> Individual results may vary.</li>
                    </ul>
                </div>
            </article>
            <picture>
                <source media="screen and (max-width: 959px)" srcset="Content/images/hero/mobile-home-doctor.png">
                <source media="screen and (max-width: 9999px) and (min-width: 960px)" srcset="Content/images/hero/desktop-home-doctor.png">
                <img src="Content/images/hero/desktop-home-doctor.png" alt="Healthcare professional." />
            </picture>

                            </div>
</div>

<div id="first_section">
    <div id="indication_bar" class="close">
	<div>
		<div class="section">
			<h3>For adult patients with moderately to severely active UC or CD when other therapies have not worked well enough or cannot be&nbsp;tolerated.</h3>
		</div>
	</div>
</div>

    <div>
        <article class="first-line-biologic">
            <div>
                <h2><strong>More UC and CD patients start on Entyvio than any other biologic<sup>8</sup>*</strong></h2>

                <div class="legal">
                    <p class="legal">*Based on an analysis of data in SHA database comparing quarterly UC and CD combined patient counts from January 2019 to May 2021 with &ldquo;new start&rdquo; defined as &ldquo;bio-na&iuml;ve&rdquo; plus &ldquo;switch&rdquo; patients. &ldquo;Bio-na&iuml;ve&rdquo; is defined as any patient with UC or CD who had no UC or CD biologic drug claims for the past 3 years. &ldquo;Switch&rdquo; is defined as any patient who previously used a different UC or CD biologic drug and switched to the current therapy in the past 3&nbsp;years. </p>
                </div>
            </div>
        </article>
    </div>


    <div id="home_title">
        <article>
            <div>
                <h2><span>Only <span>Entyvio <em>(vedolizumab)</em></span> Combines</span></h2>
            </div>
        </article>
    </div>


    <div id="pillars">
        <article>
            <div class="selectivity">
                <section class="content-area">
                    <h2><span class="knockout-29">Gut</span> Selectivity<sup>2-7</sup></h2>
                    <h3>Entyvio helps address inflammation where it occurs—the gut.<sup>1</sup></h3>
                    <p>Entyvio specifically binds to the &alpha;4&beta;7 integrin and blocks the interaction between the &alpha;4&beta;7 integrin and MAdCAM-1, which is mainly expressed on the GI tract endothelial cells.</p>
                </section>

                <div class="btn-wrapper">
                    <p><a href="mechanism-of-action.html" class="btn btn-primary" target="_self">Discover the MOA</a></p>
                </div>

                <picture>                    
                    <img class="bg" src="Content/images/backgrounds/homepage-doctor-selectivity.png" alt="Healthcare professional." />
                </picture>
            </div>

            <p data-yellow-dot-word>and</p>

            <div class="remission">
                <section class="content-area">
                    <h2><span class="knockout-29">Long-Term</span> Remission<sup>1,9,10</sup></h2>
                    <p>UC and CD patients achieved remission at Week 52 vs placebo in study populations that included bio&#8209;na&iuml;ve and anti&#8209;TNF&alpha;&#8209;<br data-only="mobile" />experienced patients.<sup>1,9,10</sup></p>
                    <p>Individual results may vary.</p>
                    <h3>Week 6 and Week 52:</h3>
                </section>

                <div class="btn-wrapper">
                    <p><a href="clinical-efficacy/ulcerative-colitis/gemini-trial.html" class="btn btn-primary" target="_self">View UC Data</a></p>
                    <p><a href="clinical-efficacy/crohns-disease/entyvio-placebo-trial.html" class="btn btn-primary" target="_self">View CD Data</a></p>
                </div>

                <picture>
                    <img class="bg" src="Content/images/backgrounds/homepage-doctor-remission.png" alt="Healthcare professional." />
                </picture>
            </div>

            <p data-yellow-dot-word>and</p>

            <div class="safety">
                <section class="content-area">
                    <h2>Safety Data<span class="knockout-29">For the Long Term<sup>1,11-13</sup></span></h2>
                    <p>Clinical trials evaluated safety in more than 3300 adults (UC, CD, and healthy volunteers).<sup>1</sup> A separate open-label study of up to 7 years demonstrated consistent results across safety parameters.<sup>11-13&dagger;</sup></p>

                    <p class="footnote"><sup>&dagger;</sup>In a single-arm, open-label extension study of 2243 patients who received Entyvio with a median exposure of 1072&nbsp;days (range 1 to 3412 days).<sup>11-13</sup></p>
                </section>

                <div class="btn-wrapper">
                    <p><a href="safety-profile.html" class="btn btn-primary" target="_self">View Safety Profile</a></p>
                </div>

                <picture>                   
                    <img class="bg" src="Content/images/backgrounds/homepage-doctor-safety.png" alt="Healthcare professional." />
                </picture>
            </div>
        </article>
    </div>


    <div id="cta">
        <article>
            <div>
                <section class="head-to-head">
                    <div class="varsity-trial">
                        <img class="" src="Content/images/logos/logo-varsity-trial.png" alt="Varsity Trial" />
                    </div>
                    <h2>
                        <span class="knockout-29">
                            ONLY ENTYVIO OFFERS RESULTS FROM THE
                        </span>

                        <span class="knockout-49">
                            first head-to-<br />head study
                        </span>

                        <span class="knockout-29 subhead">
                            of biologics in moderate to <span data-nobr="all">severe UC<sup>14-16</sup></span>
                        </span>
                    </h2>

                    <article class="entyvio-vs-humira">
                        <h3>Entyvio <em>(vedolizumab)</em></h3>
                        <div><p data-yellow-dot-word>Vs</p></div>
                        <h3>Humira<span class="superscript-set"><sup>&reg;&Dagger;</sup></span> <em>(adalimumab)</em></h3>
                    </article>

                    <p class="legal"><span><sup>&Dagger;</sup></span>Humira<sup>&reg;</sup> (AbbVie Inc., North Chicago, IL). For information related to Humira, please see AbbVie.com.</p>

                    <p class="btn-wrapper"><a class="btn btn-secondary" href="clinical-efficacy/ulcerative-colitis/varsity-trial.html" target="_self">See the study results</a></p>
                </section>
            </div>

            <div>


                <section class="milestones">
                    <h2>Reaching new milestones</h2>

                    <div class="milestones-banner">
                        <img class="" src="Content/images/graphics/new-milestones-banner.png" alt="Over 215,000 UC and CD patients in the US since the approval of Entyvio®." />
                    </div>

                    <div class="icon-list">
                        <div class="icon-item">
                            <img src="Content/images/graphics/29k_icon.png" alt="29,000 physicians." />
                            <p>
                                <span>over 29k physicians have prescribed entyvio</span><br />
                                in the US since approval<sup>18&sect;</sup>
                            </p>
                        </div>
                        <div class="icon-item">
                            <img src="Content/images/graphics/89_icon.png" alt="89% of commercially insured patients have first-line biologic unrestricted commercial coverage." />
                            <p>
                                <span>89% of commercially insured patients</span><br />
                                have first-line biologic unrestricted commercial coverage for Entyvio<sup>19&#8214;</sup>
                            </p>
                        </div>

                    </div>

                    <a class="btn btn-primary" href="local-coverage/index.html" target="_self">Check Coverage</a>

                    <div class="legal">
                        <p class="legal"><sup>&sect;</sup>This information is derived from a Symphony database of Entyvio medical and pharmacy claims from June 2014 to preliminary April 2021.</p>
                        <p class="legal"><sup>||</sup>First-line/unrestricted coverage refers to patients with no prior biologic use. Data regarding current first-line/unrestricted commercial coverage for Entyvio are derived from Managed Markets Insights &amp; Technology (MMIT) as of July 2021.</p>
                    </div>
                </section>
            </div>
        </article>
    </div>
</div>




                <!-- *********************** -->
                <!-- **** CODE ENDS **** *** -->
                <!-- *********************** -->
            </main>

            <div id="isi">
                <aside class="section">
	<article>
		<button class="fixed_isi_trigger" aria-expanded="false" aria-controls="fixed_isi" aria-label="ISI Expand Button">
            <span></span>
        </button>
        <div class="isi-header">
            <h2>Important Safety Information</h2>
        </div>
		<ul>
			<li>ENTYVIO (vedolizumab) for injection is contraindicated in patients who have had a known serious or severe hypersensitivity reaction to ENTYVIO or any of its excipients.</li>

			<li>Infusion-related reactions and hypersensitivity reactions including anaphylaxis, dyspnea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart rate have been reported. These reactions may occur with the first or subsequent infusions and may vary in their time of onset from during infusion or up to several hours post-infusion. If anaphylaxis or other serious infusion-related or hypersensitivity reactions occur, discontinue administration of ENTYVIO immediately and initiate appropriate treatment.</li>

			<li>Patients treated with ENTYVIO are at increased risk for developing infections. Serious infections have been reported in patients treated with ENTYVIO, including anal abscess, sepsis (some fatal), tuberculosis, salmonella sepsis, Listeria meningitis, giardiasis, and cytomegaloviral colitis. ENTYVIO is not recommended in patients with active, severe infections until the infections are controlled. Consider withholding ENTYVIO in patients who develop a severe infection while on treatment with ENTYVIO. Exercise caution in patients with a history of recurring severe infections. Consider screening for tuberculosis (TB) according to the local practice.</li>

			<li>Progressive multifocal leukoencephalopathy (PML), a rare and often fatal opportunistic infection of the central nervous system (CNS), has been reported with systemic immunosuppressants, including another integrin receptor antagonist. PML is caused by the John Cunningham (JC) virus and typically only occurs in patients who are immunocompromised. One case of PML in an ENTYVIO-treated patient with multiple contributory factors has been reported in the postmarketing setting (e.g., human immunodeficiency virus [HIV] infection with a CD4 count of 300 cells/mm<sup>3</sup> and prior and concomitant immunosuppression). Although unlikely, a risk of PML cannot be ruled out. Monitor patients for any new or worsening neurological signs or symptoms. Typical signs and symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. If PML is suspected, withhold dosing with ENTYVIO and refer to a neurologist; if confirmed, discontinue ENTYVIO dosing permanently.</li>

			<li>There have been reports of elevations of transaminase and/or bilirubin in patients receiving ENTYVIO. ENTYVIO should be discontinued in patients with jaundice or other evidence of significant liver injury.</li>

			<li>Prior to initiating treatment with ENTYVIO, all patients should be brought up to date with all immunizations according to current immunization guidelines. Patients receiving ENTYVIO may receive non-live vaccines and may receive live vaccines if the benefits outweigh the risks.</li>

			<li>Most common adverse reactions (incidence ≥3% and ≥1% higher than placebo): nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, and pain in extremities.</li>
		</ul>

		<h2>Indications</h2>
		<h3>Adult Ulcerative Colitis (UC)</h3>
		<p>ENTYVIO (vedolizumab) is indicated in adults for the treatment of moderately to severely active UC.</p>

		<h3>Adult Crohn's Disease (CD)</h3>
		<p>ENTYVIO (vedolizumab) is indicated in adults for the treatment of moderately to severely active CD.</p>

		<p>Please see <a href="https://general.takedapharm.com/ENTYVIOPI" target="_blank" rel="noreferrer">full Prescribing Information</a>, including <a href="https://general.takedapharm.com/ENTYVIOMG" target="_blank" rel="noreferrer">Medication Guide</a>.</p>
	</article>
</aside>

            </div>

                <div id="references">
                    <div class="section">
                        <article>
                            <h3>References:</h3>
                            
    <ol>
        <li>Entyvio (vedolizumab) prescribing information. Takeda Pharmaceuticals.</li>
        <li>Briskin M, Winsor-Hines D, Shyjan A, et al. <em>Am J Pathol</em>. 1997;151(1):97-110.</li>
        <li>Fedyk E, Wyant T, Yang LL, et al. <em>Inflamm Bowel Dis</em>. 2012;18(11):2107<span>-</span>2119.</li>
        <li>Soler D, Chapman T, Yang LL, et al. <em>J Pharmacol Exp Ther</em>. 2009;330(3):864-875.</li>
        <li>Wyant T, Fedyk E, Abhyankar B. <em>J Crohns Colitis</em>. 2016;10(12):1437-1444.</li>
        <li>Wyant T, Leach T, Sankoh S, et al. <em>Gut</em>. 2015;64(1):77-83.</li>
        <li>Milch C, Wyant T, Xu J, et al. <em>J Neuroimmunol</em>. 2013;264:123-126.</li>
        <li>Data on file. Entyvio is the most prescribed biologic in IBD new patient starts - Supporting Data & Methodology Overview, August 2021. Takeda Pharmaceuticals USA, Inc.</li>
        <li>Data on file. MLN0002, Final CSR C13006, September 2012. Takeda Pharmaceuticals USA, Inc.</li>
        <li>Data on file. MLN0002, Final CSR C13007, October 2012. Takeda Pharmaceuticals USA, Inc.</li>
        <li>Loftus EV, Feagan BG, Panaccione R, et al; for the GEMINI LTS study team. <em>Aliment Pharmacol Ther</em>. 2020;00:1-13.</li>
        <li>Data on file. MLN0002, Final CSR C13008, July 2018. Takeda Pharmaceuticals USA, Inc.</li>
        <li>Data on file. Internal communication, October 2020. Takeda Pharmaceuticals USA, Inc.</li>
        <li>Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. <em>N Engl J Med</em>. 2019;381(13):1215-1226.</li>
        <li>Data on file. DDW Abstract 416a, May 2019. Takeda Pharmaceuticals USA, Inc.</li>
        <li>Data on file. DDW Oral Presentation 416a, May 2019. Takeda Pharmaceuticals USA, Inc.</li>
        <li>Data on file. Entyvio Patient Counts - Supporting Data &amp; Methodology Overview, June 2021. Takeda Pharmaceuticals USA, Inc.</li>
        <li>Data on file. Entyvio Prescriber Counts - Supporting Data &amp; Methodology Overview, June 2021. Takeda Pharmaceuticals USA, Inc.</li>
        <li>Data on file. Entyvio Access Report, September 2021. Takeda Pharmaceuticals USA, Inc.</li>

    </ol>

                        </article>
                    </div>
                </div>

            <footer id="footer" data-device="global">
    <div>
        <div class="section">
            <div class="footer-content">
                <a class="takeda-logo" data-modal="external" data-animation="slide" href="http://www.takeda.com/" target="_blank" rel="noreferrer"><img src="Content/images/logos/logo-takeda.svg" alt="Takeda Pharmaceuticals U.S.A., Inc. logo." /></a>
                <div class="nav-wrapper">
                    <nav>
                        <ul>
                            <li><a data-modal="external" data-animation="slide" href="https://www.takeda.com/en-us/terms-of-use" target="_blank" rel="noreferrer">Terms of Use</a></li>
                            <li><a data-modal="external" data-animation="slide" href="https://www.takeda.com/privacy-notice/" target="_blank" rel="noreferrer">Privacy Notice</a></li>
                            <li><a data-modal="external" data-animation="slide" href="https://www.takeda.com/en-us/who-we-are/contact-us" target="_blank" rel="noreferrer">Contact Us</a></li>
                            <li class=""><a href="sitemap.html" target="_self">Site Map</a></li>
                        </ul>
                        <ul>
                            <li><a data-modal="external" data-animation="slide" href="https://www.takedahcp.com/unsubscribe/enrx" target="_blank" rel="noreferrer">Unsubscribe</a></li>
                            <li><a data-modal="external" data-animation="slide" href="https://www.takedahcp.com/" target="_blank" rel="noreferrer">Professional Support</a></li>
                            <li><a data-modal="external_medconnect" data-animation="slide" href="https://www.takedamedconnect.com/" target="_blank" rel="noreferrer">Medical Information</a></li>
                        </ul>
                    </nav>

                    <p>ENTYVIO is a trademark of Millennium Pharmaceuticals, Inc., registered with the U.S. Patent and Trademark Office and is used under license by Takeda Pharmaceuticals America, Inc. All other trademarks are the property of their respective owners.</p>

                    <p>If you are a Colorado prescriber, please see the Colorado WAC <a data-modal="external" href="https://www.takeda.com/siteassets/en-us/home/corporate-responsibility/culture-of-compliance/state/co_entyvio-product-form.pdf" target="_blank" rel="noreferrer">disclosure form</a>.</p>

                    <p>
                        &copy;2021 Takeda&nbsp;Pharmaceuticals U.S.A., Inc.<br />
                        This site is intended for use by U.S. residents only.  
                    <span data-float="right">US-VED-1124v1.0 10/21</span>
                    </p>
                </div>
            </div>
        </div>
    </div>
</footer>
        </div>
    </div>

    <div id="fixed_isi">
        <aside class="section">
	<article>
		<button class="fixed_isi_trigger" aria-expanded="false" aria-controls="fixed_isi" aria-label="ISI Expand Button">
            <span></span>
        </button>
        <div class="isi-header">
            <h2>Important Safety Information</h2>
        </div>
		<ul>
			<li>ENTYVIO (vedolizumab) for injection is contraindicated in patients who have had a known serious or severe hypersensitivity reaction to ENTYVIO or any of its excipients.</li>

			<li>Infusion-related reactions and hypersensitivity reactions including anaphylaxis, dyspnea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart rate have been reported. These reactions may occur with the first or subsequent infusions and may vary in their time of onset from during infusion or up to several hours post-infusion. If anaphylaxis or other serious infusion-related or hypersensitivity reactions occur, discontinue administration of ENTYVIO immediately and initiate appropriate treatment.</li>

			<li>Patients treated with ENTYVIO are at increased risk for developing infections. Serious infections have been reported in patients treated with ENTYVIO, including anal abscess, sepsis (some fatal), tuberculosis, salmonella sepsis, Listeria meningitis, giardiasis, and cytomegaloviral colitis. ENTYVIO is not recommended in patients with active, severe infections until the infections are controlled. Consider withholding ENTYVIO in patients who develop a severe infection while on treatment with ENTYVIO. Exercise caution in patients with a history of recurring severe infections. Consider screening for tuberculosis (TB) according to the local practice.</li>

			<li>Progressive multifocal leukoencephalopathy (PML), a rare and often fatal opportunistic infection of the central nervous system (CNS), has been reported with systemic immunosuppressants, including another integrin receptor antagonist. PML is caused by the John Cunningham (JC) virus and typically only occurs in patients who are immunocompromised. One case of PML in an ENTYVIO-treated patient with multiple contributory factors has been reported in the postmarketing setting (e.g., human immunodeficiency virus [HIV] infection with a CD4 count of 300 cells/mm<sup>3</sup> and prior and concomitant immunosuppression). Although unlikely, a risk of PML cannot be ruled out. Monitor patients for any new or worsening neurological signs or symptoms. Typical signs and symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. If PML is suspected, withhold dosing with ENTYVIO and refer to a neurologist; if confirmed, discontinue ENTYVIO dosing permanently.</li>

			<li>There have been reports of elevations of transaminase and/or bilirubin in patients receiving ENTYVIO. ENTYVIO should be discontinued in patients with jaundice or other evidence of significant liver injury.</li>

			<li>Prior to initiating treatment with ENTYVIO, all patients should be brought up to date with all immunizations according to current immunization guidelines. Patients receiving ENTYVIO may receive non-live vaccines and may receive live vaccines if the benefits outweigh the risks.</li>

			<li>Most common adverse reactions (incidence ≥3% and ≥1% higher than placebo): nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, and pain in extremities.</li>
		</ul>

		<h2>Indications</h2>
		<h3>Adult Ulcerative Colitis (UC)</h3>
		<p>ENTYVIO (vedolizumab) is indicated in adults for the treatment of moderately to severely active UC.</p>

		<h3>Adult Crohn's Disease (CD)</h3>
		<p>ENTYVIO (vedolizumab) is indicated in adults for the treatment of moderately to severely active CD.</p>

		<p>Please see <a href="https://general.takedapharm.com/ENTYVIOPI" target="_blank" rel="noreferrer">full Prescribing Information</a>, including <a href="https://general.takedapharm.com/ENTYVIOMG" target="_blank" rel="noreferrer">Medication Guide</a>.</p>
	</article>
</aside>

    </div>
    <!-- MODAL STARTS -->
<div id="modal" role="dialog" aria-modal="true" aria-labelledby="modal_content" data-modal-animation="slide">
	<div id="modal_content">
		<button class="close" aria-label="Close"><span></span></button>

		<section class="content" data-modal-content="external_medconnect">
			<h2>You are about to leave this website.</h2>
			<p>By clicking "Continue," you will leave this site and enter TakedaMedConnect.com. The information contained on Takeda MedConnect is intended for U.S. healthcare professionals only in response to a specific request for medical information.</p>
			<div class="modal-footer">
				<button class="btn btn-secondary close">Cancel</button>
				<a class="btn btn-secondary external" href="#" target="_blank" rel="noreferrer">Continue</a>
			</div>
		</section>


		<section class="content" data-modal-content="external">
			<h2>You are about to leave this website.</h2>
			<div class="modal-footer">
				<button class="btn btn-secondary close">Cancel</button>
				<a class="btn btn-secondary external" href="#" target="_blank" rel="noreferrer">Continue</a>
			</div>
		</section>


		<section class="content" data-modal-content="external_third_party"> 
			<h2>You are about to leave this website and enter a website operated by an independent third party.</h2>
			<p>The links to third-party websites contained on this website are provided solely for your convenience. Takeda does not control the content contained on any third-party website linked from this website. Your activities at those websites will be governed by the policies and practices of those third parties.</p>

			<p>Please select "Continue" if you wish to be taken to this third-party website.</p>
			<div class="modal-footer">
				<button class="btn btn-secondary close">Cancel</button>
				<a class="btn btn-secondary external" href="#" target="_blank" rel="noreferrer">Continue</a>
			</div>
		</section>

	</div>
	<strong></strong>
</div>
<!-- MODAL ENDS -->
    
    <button class="back-to-top btn btn-secondary" tabindex="0">Back to top</button>

    <script>
        const pauseVideo = (id, time) => {
            const video = document.getElementById(id);
            video.pause();
            video.classList.add('playing');
            video.currentTime = time;
        },
            homepage_hover = () => {
                document.querySelector('.head-to-head .btn').classList.add('hover');
                document.querySelector('.btn[href="/mechanism-of-action"]').classList.add('hover');
            },
            Extra_Form_Errors = () => {
                setTimeout(function () {
                    document.querySelectorAll('input, select').forEach(element => element.blur());
                    document.getElementById('Email-error').innerHTML = '<span class="ed-templating">[</span>Please enter your email address.<span class="ed-templating">]</span><br /><span class="ed-templating">[</span>Please enter a valid email address.<span class="ed-templating">]</span>';
                    document.getElementById('Zip-error').innerHTML = '<span class="ed-templating">[</span>Please enter your ZIP code.<span class="ed-templating">]</span><br /><span class="ed-templating">[</span>Please enter a valid ZIP code.<span class="ed-templating">]</span>';
                    document.getElementById('Server-error').innerHTML = 'Sorry, an error occurred while processing your request.';
                }, 1000);
            };
    </script>

    <!--<script type="text/javascript">_satellite.pageBottom();</script>-->

</body>

<!-- Mirrored from www.entyviohcp.com/ by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 14 Feb 2022 03:29:59 GMT -->
</html>